18:47 , Jul 21, 2017 |  BC Week In Review  |  Clinical News

BD FACSLyric diagnostic gets 510(k) clearance from FDA

FDA granted 510(k) clearance to BD FACSLyric flow cytometer system from Becton Dickinson and Co. (NYSE:BDX). The in vitro diagnostic system is for use with the company’s BD Multitest assays to detect immune deficiency. Becton...
22:29 , Jun 15, 2017 |  BC Extra  |  Company News

Twist, BioBricks launching open gene forum

Twist Bioscience Corp. (San Francisco, Calif.) and BioBricks Foundation (San Francisco, Calif.) partnered to create an open online forum for researchers to suggest and vote on genes for manufacture. BioBricks will pay for synthesis of...
00:17 , Apr 29, 2017 |  BioCentury  |  Finance

Earnings on deck

Earnings on deck At least 19 biotechs and pharmas are expected to report earnings this week. (A) Fiscal 2Q; (B) Fiscal 3Q Company Date Pre/post mkt 1Q17 EPS est 1Q16 EPS Expected chg Luminex Corp....
00:24 , Dec 23, 2016 |  BC Extra  |  Company News

Management tracks

As part of a restructuring, fertility company OvaScience Inc. (NASDAQ:OVAS) said President and CEO Harald Stock and COO Paul Chapman will leave the company. OvaScience is also reducing headcount by about 30%, slowing commercial expansion...
07:00 , Oct 31, 2016 |  BioCentury  |  Finance

Quark’s global ambitions

After getting its toes wet with a couple of biotech seed investments and hiring a drug development veteran as partner and CEO, Canadian VC Quark Venture Inc. teamed up with GF Securities Co. Ltd. (SZSE:000776;...
07:00 , Sep 20, 2016 |  BC Extra  |  Politics & Policy

HELP committee hears testimony on LDT oversight

Members of the U.S. Senate Health, Education, Labor and Pensions Committee and the four witnesses who testified in front of the committee on Tuesday agreed that there is a need for more oversight of laboratory-developed...
07:00 , Aug 1, 2016 |  BioCentury  |  Finance

Gilead's arithmetic problem

Declining HCV sales and lower guidance from Gilead Sciences Inc. (NASDAQ:GILD) shaved about $10 billion off the bellwether's market cap last Tuesday and renewed investor calls for the company to do a splashy deal to...
07:00 , Jun 6, 2016 |  BioCentury  |  Finance

Rushing to America

Biotechs in the U.S. are seeing a surge of interest from Chinese investors that reflects myriad motives. These range from a desire to access assets to serve a domestic market that is hungry for innovative...
07:00 , May 2, 2016 |  BioCentury  |  Finance

Private payday

AbbVie Inc. (NYSE:ABBV) is paying an eye-popping $5.8 billion up front and a potential $4 billion in milestones for privately held Stemcentrx Inc. , but the pharma thinks the price is worth it to obtain...
08:00 , Feb 22, 2016 |  BC Week In Review  |  Clinical News

BD FACSPresto Near-Patient CD4 Counter system regulatory update

FDA granted 510(k) clearance to Becton Dickinson’s BD FACSPresto system and BD FACSPresto CD4/Hb Cartridge to measure absolute and percentage results of CD4 T lymphocytes and hemoglobin concentration in blood samples from HIV/AIDS patients. Using...